Time to Improvise: M&A Megatrends
2018
2017 was a comparatively quiet year for pharma M&A. However, conditions remain ripe for companies to engage in more deal making in 2018. Big Pharma is divesting its non-core assets and doubling down on core business lines. Furthermore, generics portfolios are increasingly being seen as underperforming assets that distract from the bread and butter of developing high-margin innovative drugs – making them ripe for divestment and consolidation.
Other trends covered include major asset swaps between Big Pharma, the success of companies which have indulged in serial M&A such as Allergan and Valeant, the increasing importance of acquiring digital assets, and how CMOs are fast catching up with CROs in both volume and value of consolidation deals.
2017 was a comparatively quiet year for pharma M&A. However, conditions remain ripe for companies to engage in more deal making in 2018. Big Pharma is divesting its non-core assets and doubling down on core business lines. Furthermore, generics portfolios are increasingly being seen as underperforming assets that distract from the bread and butter of developing high-margin innovative drugs – making them ripe for divestment and consolidation.
Other trends covered include major asset swaps between Big Pharma, the success of companies which have indulged in serial M&A such as Allergan and Valeant, the increasing importance of acquiring digital assets, and how CMOs are fast catching up with CROs in both volume and value of consolidation deals.
